Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Livzon Pharmaceutical Group ( (HK:1513) ) has shared an update.
Livzon Pharmaceutical Group Inc. has proposed the election of Ms. Wang Zhiyao as an independent non-executive director to replace retiring directors Mr. Tian Qiusheng and Mr. Wong Kam Wa. Ms. Wang’s appointment is pending approval at the 2025 extraordinary general meeting and is expected to bring her extensive experience in the pharmaceutical and biotechnology sectors to the company, potentially enhancing its strategic direction and governance.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. operates in the pharmaceutical industry, focusing on the development, production, and sale of pharmaceutical products. The company is known for its comprehensive range of healthcare solutions and aims to maintain a strong market presence in the pharmaceutical sector.
YTD Price Performance: 20.79%
Average Trading Volume: 1,341,695
Technical Sentiment Signal: Buy
Current Market Cap: HK$34.3B
For detailed information about 1513 stock, go to TipRanks’ Stock Analysis page.